Wed Sep 25 07:44:54 UTC 2024: ## Protagonist Therapeutics (PTGX) Receives Buy Rating from TD Cowen, Attracting Investor Interest

**New York, NY -** Protagonist Therapeutics (PTGX), a biopharmaceutical company focused on developing peptide-based drugs for various medical conditions, is attracting significant attention from investors. TD Cowen initiated coverage on the stock with a “Buy” rating and a $65.00 price target, adding to the positive sentiment surrounding the company.

Several other analysts have also expressed bullish sentiment. BTIG Research lifted their target price to $51.00, JMP Securities lowered their target price but maintained a “Market Outperform” rating, and HC Wainwright boosted their target price to $50.00, all while maintaining “Buy” recommendations.

Protagonist Therapeutics recently reported its quarterly earnings, meeting analyst expectations with a revenue of $4.17 million. While the company is still in the early stages of development, analysts anticipate significant growth in the future, projecting a 2.31 EPS for the current fiscal year.

Despite the positive outlook, there have been recent insider sales of shares. CFO Asif Ali sold 14,203 shares and Director William D. Waddill sold 8,000 shares. However, it’s important to note that insider trading can be influenced by various factors and doesn’t necessarily reflect a negative view on the company’s future prospects.

Institutional investors remain optimistic, with several hedge funds increasing their holdings in Protagonist Therapeutics. Notably, Farallon Capital Management LLC increased its position by 1.8%, Vanguard Group Inc. by 1.2%, and Millennium Management LLC by a significant 2,135.6%.

Overall, Protagonist Therapeutics appears to be attracting interest from both analysts and institutional investors. The company’s focus on developing innovative peptide-based drugs for hematology, blood disorders, and inflammatory diseases has the potential to address significant unmet medical needs. However, it’s important for investors to conduct their own research and consider the risks associated with investing in a company in the early stages of development.

Read More